Moreover, the 36-month beta value for PTPI is 2.16. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 1.75M and currently, short sellers hold a 28.22% of that float. On May 12, 2025, PTPI’s average trading volume was 3.47M shares.
PTPI) stock’s latest price update
Petros Pharmaceuticals Inc (NASDAQ: PTPI)’s stock price has decreased by -4.23 compared to its previous closing price of 0.13. However, the company has seen a -51.77% decrease in its stock price over the last five trading sessions. accessnewswire.com reported 2025-05-06 that Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) (“Petros” or the “Company”), a company focused on expanding consumer access to medication through over the counter (“OTC”) drug development programs, today announces it has implemented multiple enhancements to its developing AI platform, which is expected to improve processing and fraud detection and provide a better overall experience. The AI Platform is expected to be a key component of the Company’s recently announced SaaS-based technology, integrating Petros’ Software as a Medical Device (“SaMD”) proprietary solution, which is being designed to help facilitate expanding access for established prescription drugs by bringing them over the counter.
PTPI’s Market Performance
PTPI’s stock has fallen by -51.77% in the past week, with a monthly drop of -90.73% and a quarterly drop of -98.14%. The volatility ratio for the week is 43.05% while the volatility levels for the last 30 days are 40.22% for Petros Pharmaceuticals Inc The simple moving average for the past 20 days is -84.17% for PTPI’s stock, with a -98.13% simple moving average for the past 200 days.
PTPI Trading at -92.11% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.33% of loss for the given period.
Volatility was left at 40.22%, however, over the last 30 days, the volatility rate increased by 43.05%, as shares sank -89.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -95.33% lower at present.
During the last 5 trading sessions, PTPI fell by -51.77%, which changed the moving average for the period of 200-days by -98.86% in comparison to the 20-day moving average, which settled at $0.7586. In addition, Petros Pharmaceuticals Inc saw -98.78% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.46 for the present operating margin
- 0.76 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -3.95. The total capital return value is set at 2.39.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated -90.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at -0.99. The interest coverage ratio of the stock is -31.52.
Currently, EBITDA for the company is -10.81 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 0.77. The receivables turnover for the company is 12.29for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
To wrap up, the performance of Petros Pharmaceuticals Inc (PTPI) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
